Catecholamines and Pituitary Function.

The inhibitory effect of various doses of dopamine on serum PRL levels was assessed in both normal cycling women and patients with tumoral hyperprolactinemia before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine, a strong and specific tyrosine-hydroxylase inhibitor. Dopamine infusion induced a significant decrease in the serum PRL levels in both normal cycling and hyperprolactinemic subjects. The mean percent inhibition of baseline PRL induced by the various dopamine infusion rates (0.1, 0.5, 1.0 and 2.0 micrograms/kg/min) was similar in regularly cycling women and in patients with tumoral hyperprolactinemia both before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine. Alpha-methyl-p-tyrosine pretreatment significantly increased serum PRL concentrations in normal women and enhanced their responsiveness to the exogenously administered dopamine. Hyperprolactinemic patients, on the contrary, did not show any significant variation in either basal PRL release or the PRL sensitivity to dopamine infusion after endogenous catecholamine synthesis inhibition. These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors.

[1]  O. Serri,et al.  Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. , 1983, The Journal of clinical endocrinology and metabolism.

[2]  P. Woolf,et al.  Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. , 1981, The American journal of medicine.

[3]  I. Nicoletti,et al.  Effect of estrogens and progesterone on gonadotropin and prolactin release in a patient with androgen insensitivity. , 1981, Obstetrics and gynecology.

[4]  I. Nicoletti,et al.  Progesterone positive feedback on gonadotropin release in estrogen-primed postmenopausal women: central nervous system and pituitary as possible sites of action. , 1981, The Journal of clinical endocrinology and metabolism.

[5]  I. Nicoletti,et al.  Methyl-P-Tyrosine Effect on Gonadotropin and Prolactin Pituitary Release in Women , 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[6]  J. C. Porter,et al.  Prolactin augmentation of dopamine and norepinephrine release from superfused medial basal hypothalamic fragments. , 1981, Endocrinology.

[7]  P. Plotsky,et al.  Dopamine in hypophysial stalk blood of the rhesus monkey and its role in regulating prolactin secretion. , 1981, Endocrinology.

[8]  S. Yen,et al.  Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. , 1981, The Journal of clinical endocrinology and metabolism.

[9]  M. Meschia,et al.  EFFECT OF DOPAMINE INFUSION ON SERUM PROLACTIN CONCENTRATION IN NORMAL AND HYPERPROLACTINAEMIC SUBJECTS , 1980, Clinical endocrinology.

[10]  M. Martres,et al.  Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. , 1980, The Journal of clinical endocrinology and metabolism.

[11]  A. Genazzani,et al.  Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. , 1980, The Journal of clinical endocrinology and metabolism.

[12]  S. Yen,et al.  Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. , 1980, The Journal of clinical endocrinology and metabolism.

[13]  C. Wilson,et al.  [3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. , 1980, The Journal of clinical endocrinology and metabolism.

[14]  J. C. Porter,et al.  Secretion of dopamine into hypophysial portal blood by rats bearing prolactin-secreting tumors or ectopic pituitary glands. , 1979, Endocrinology.

[15]  S. Yen,et al.  Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels. , 1978, The Journal of clinical endocrinology and metabolism.

[16]  J. D. Neill,et al.  Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. , 1978, Endocrinology.

[17]  L. Frohman,et al.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. , 1978, The Journal of clinical investigation.

[18]  G. Molinatti,et al.  Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. , 1977, The Journal of clinical endocrinology and metabolism.

[19]  C. Oliver,et al.  Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. , 1977, Endocrinology.

[20]  S. Yen,et al.  Effects of dopamine infusion on pituitary hormone secretion in humans. , 1976, The Journal of clinical endocrinology and metabolism.

[21]  J. Sowers,et al.  Metoclopramide stimulates prolactin secretion in man. , 1976, The Journal of clinical endocrinology and metabolism.

[22]  J. Letarte,et al.  Endocrine effects of pimozide, a specific dopaminergic blocker. , 1975, The Journal of clinical endocrinology and metabolism.

[23]  A. Sjoerdsma,et al.  Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. , 1968, The Journal of clinical investigation.

[24]  T. Hökfelt,et al.  The possible ultrastructural identification of tubero-infundibular dopamine containing nerve endings in the median eminence of the rat. , 1967, Brain research.

[25]  A. Sjoerdsma,et al.  Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. , 1965, Lancet.

[26]  K. Kovacs,et al.  Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. , 1982, The Journal of clinical endocrinology and metabolism.

[27]  D. Cocchi,et al.  Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. , 1980, Neuroendocrinology.

[28]  G. van Loon.  A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma. , 1978, Lancet.

[29]  G. Molinatti,et al.  Inhibition of thyrotropin and prolactin secretion by dopamine in man , 1978, Journal of endocrinological investigation.

[30]  K. E. Moore,et al.  Increased ability of apomorphine to reduce serum concentrations of prolactin in rats treated chronically with alpha-methyltyrosine. , 1977, Life sciences.